DISCLAIMER: Reader comments posted on this website are in no way endorsed by Manila Standard. Comments are the opinions of the readers of manilastandard.net exercising their right to free speech and do not necessarily represent or reflect the position or point of view of manilastandard.net. While reserving the right in this post to remove comments deemed offensive, indecent, or inconsistent with Manila Standard’s editorial standards, Manila Standard cannot be held responsible for any false information posted by readers in this comments section.
President Rodrigo Duterte has ordered to regulate the prices of more drugs and drugs used to fight the main causes of morbidity in the country, said Malacañang. The President on Tuesday signed Decree 155 which fixes the maximum retail price and / or the maximum wholesale price for 34 drug molecules or 71 drug formulas used in agents affecting bone metabolism, analgesics, anesthetics, antianginal drugs , antiarrhythmics, anti-asthmatics and drugs for chronic obstructive pulmonary disease, antibiotics, anticoagulants, anticonvulsants, antidiabetic drugs, antidiuretics and antiemetics. EO 155 also covers drug formulations used in anti-glaucoma, anti-hypercholesterolemic, antihypertensive, anti-neoplastic / anti-cancer drugs, anti-parkinsonian drugs, overactive bladder drugs, growth hormone inhibitors, immunosuppressants, iron chelators. medicines for psoriasis, seborrhea and ichthyosis. The EO requires all manufacturers, importers, distributors, wholesalers, traders and retailers to “display the retail price which must not exceed the MRP,” Malacañang said Wednesday. “After conducting a price review using international benchmark pricing methods among ASEAN countries, mark-up regulation and stakeholder consultation, the TWG [Technical Working Group] recommended, and the DOH [Department of Health] approved the imposition of MPR and MWP on the remaining drug formulations of certain drugs and drugs, ”the OE said. “In accordance with the overall strategy of RA 11223 or the Universal Health Care Act to improve access to affordable and quality medicines and reduce direct health-related expenses of Filipinos, there is a need to ‘impose more MRP and MWP on other drugs and drugs commonly used for the main causes of morbidity in the country, “he added. The OE stated: “Each manufacturer, importer, distributor, wholesaler, trader or retailer of a drug / drug intended for sale must display the retail price which must not exceed the MRP. The MRP, preceded by the words “Retail selling price not to be exceeded” and “Under the regulation of drug prices” in a red stripe, must be clearly printed on the label of the immediate container of the drug and drug. and on the minimum packaging thereof offered for retail sale. . “Labeling should also be applied to drug formulas or drugs under MRP up to EO 104.”